Immunoglobulin E specific for Phleum pratense allergen 6 (IgE Phl p 6)

Immunoglobulin E (IgE) specific for Phleum pratense allergen 6 (Phl p 6) is a key mediator of Type I hypersensitivity reactions to Timothy grass pollen, a major cause of seasonal allergic rhinitis and asthma (Source: WHO/IUIS Allergen Nomenclature). Phl p 6 is a small, 11 kDa protein that is highly cross-reactive with other grass species, making it a significant target for diagnostic and therapeutic interventions (Source: UniProt P43215). When Phl p 6 allergens cross-link specific IgE molecules bound to the high-affinity FcεRI receptors on mast cells and basophils, they trigger the rapid release of inflammatory mediators such as histamine, leading to clinical symptoms (Source: PubMed PMID: 10431357). Therapeutic approaches include the use of anti-IgE monoclonal antibodies like omalizumab, which sequester circulating IgE to prevent receptor binding, and allergen-specific immunotherapy (AIT), which utilizes standardized Timothy grass extracts to induce immune tolerance and shift the antibody profile from IgE to protective IgG4 (Source: PubMed PMID: 22405113). Measurement of Phl p 6-specific IgE levels serves as a critical biomarker for patient sensitization profiles and for monitoring the progress of desensitization therapies (Source: PubMed PMID: 11149994).

Other names

Anti-Phl p 6 IgETimothy grass pollen allergen Phl p 6-specific IgEPhl p 6-specific IgEImmunoglobulin E specific for Phl p 6

Omalizumab binds to the Cε3 domain of the IgE heavy chain, preventing the interaction of IgE with the high-affinity FcεRI receptor on mast cells and basophils. Allergen-specific immunotherapy (AIT) involves the administration of Phl p 6-containing extracts to induce regulatory T cells and allergen-specific IgG4 antibodies, which act as blocking antibodies to prevent IgE-mediated mast cell degranulation.